VIDEO: Post hoc analyses begin to show less vision loss with GA treatments

ByCarl D. Regillo, MD

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

NEW YORK — In this Healio Video Perspective from OSN New York Retina, Carl D. Regillo, MD, discusses his presentation on the latest data from the phase 3 studies of pegcetacoplan and avacincaptad pegol for treating geographic atrophy.

“At first we weren’t seeing any specific visual benefits from the drugs, but we are now seeing a variety of post hoc analyses from these studies that are indicating that patients are less likely to lose vision or have less vision loss over time if they start with good visual acuity, so it points to the benefits of identifying GA early and treating patients earlier before they lose visual acuity,” Regillo said.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Regillo reports being a clinical trial investigator and consultant to Apellis and Iveric Bio.

OSN New York and OSN New York Retina

Read more

VIDEO: Post hoc analyses begin to show less vision loss with GA treatments

Related Content